Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects

INTRODUCTION: Metformin and glucagon‐like peptide‐1 (GLP‐1) agonists are widely used for treating type two diabetes mellitus (T2DM). While recent studies suggest these drugs might modify the gastrointestinal tract (GIT) microbiome, further confirmation is required from human clinical trials. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhang, Saha, Somdutta, Van Horn, Stephanie, Thomas, Elizabeth, Traini, Christopher, Sathe, Ganesh, Rajpal, Deepak K., Brown, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360918/
https://www.ncbi.nlm.nih.gov/pubmed/30815546
http://dx.doi.org/10.1002/edm2.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360918/
https://www.ncbi.nlm.nih.gov/pubmed/30815546
http://dx.doi.org/10.1002/edm2.9

Ejemplares similares